BR112015026122A8 - agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit - Google Patents

agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit Download PDF

Info

Publication number
BR112015026122A8
BR112015026122A8 BR112015026122A BR112015026122A BR112015026122A8 BR 112015026122 A8 BR112015026122 A8 BR 112015026122A8 BR 112015026122 A BR112015026122 A BR 112015026122A BR 112015026122 A BR112015026122 A BR 112015026122A BR 112015026122 A8 BR112015026122 A8 BR 112015026122A8
Authority
BR
Brazil
Prior art keywords
methods
peg
kit
agent
pharmaceutical composition
Prior art date
Application number
BR112015026122A
Other languages
English (en)
Other versions
BR112015026122A2 (pt
Inventor
Oft Martin
Original Assignee
Armo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armo Biosciences Inc filed Critical Armo Biosciences Inc
Publication of BR112015026122A2 publication Critical patent/BR112015026122A2/pt
Publication of BR112015026122A8 publication Critical patent/BR112015026122A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

abstract: methods of using interleukin-10 for treating diseases and disorders methods of treating subjects having a disease or disorder responsive to il-10, including methods of administration and dosing regimens associated therewith, are provided. _______________________________________________________________________ resumo métodos para usar interleucina-10 para tratar doenças e desordens métodos para tratar sujeitos tendo uma doença ou desordem responsiva a il-10, incluindo métodos de administração e regimes de dosagem associados aos mesmos, são providos.
BR112015026122A 2013-04-18 2014-04-15 agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit BR112015026122A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361813563P 2013-04-18 2013-04-18
PCT/US2014/034247 WO2014172392A1 (en) 2013-04-18 2014-04-15 Methods of using interleukin-10 for treating diseases and disorders

Publications (2)

Publication Number Publication Date
BR112015026122A2 BR112015026122A2 (pt) 2017-07-25
BR112015026122A8 true BR112015026122A8 (pt) 2020-01-21

Family

ID=51731807

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015026122A BR112015026122A8 (pt) 2013-04-18 2014-04-15 agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit

Country Status (11)

Country Link
US (3) US9943568B2 (pt)
EP (1) EP2986306A4 (pt)
JP (2) JP2016519108A (pt)
CN (2) CN106913865A (pt)
AU (1) AU2014254019B2 (pt)
BR (1) BR112015026122A8 (pt)
CA (1) CA2908198A1 (pt)
HK (1) HK1215681A1 (pt)
MX (1) MX2015014438A (pt)
RU (1) RU2679889C2 (pt)
WO (1) WO2014172392A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037936T2 (hu) * 2008-12-17 2018-09-28 Merck Sharp & Dohme Mono- és di-pegil IL-10 elõállítása és alkalmazása
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
EP3038642A4 (en) * 2013-08-30 2017-01-18 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP6660297B2 (ja) 2013-11-11 2020-03-11 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を処置するためのインターロイキン−１０の使用方法
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
JP6675394B2 (ja) * 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害の治療のためにインターロイキン−１０を使用する方法
WO2016126615A1 (en) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2016268403A1 (en) * 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CA2986774A1 (en) * 2015-05-29 2016-12-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3341012A4 (en) * 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
EP3400067A4 (en) * 2016-01-05 2019-08-21 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
EP3402512A4 (en) 2016-01-11 2019-09-25 Armo Biosciences, Inc. INTERLEUKIN-10 FOR USE IN THE PRODUCTION OF ANTIGEN-SPECIFIC CD8 + T LYMPHOCYTES AND METHODS OF USE THEREOF
WO2020198831A1 (pt) 2019-04-05 2020-10-08 Universidade Federal de Uberlândia Peptídeos sintéticos com afinidade ao receptor de interleucina-10, composição farmacêutica e uso dos mesmos como imunomuduladores no tratamento de doenças autoimunes, inflamatórias ou alérgicas
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法
US11673930B2 (en) 2020-05-12 2023-06-13 Regeneran Pharmaceuticals, Inc. IL10 agonists and methods of use thereof
WO2023114958A1 (en) * 2021-12-16 2023-06-22 Xalud Therapeutics, Inc. Dosing regimen for il-10 encoding expression construct
WO2023137227A1 (en) * 2022-01-14 2023-07-20 Karma Biotechnologies Multi-vesicular lipid nanoparticle tolerogenic vaccines for induction of systemic immune tolerance in vivo
WO2024058196A1 (en) * 2022-09-13 2024-03-21 Okinawa Institute Of Science And Technology School Corporation New synthetic drugs for treating alzheimer's disease

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63152393A (ja) 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5032396A (en) 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE124866T1 (de) 1991-01-16 1995-07-15 Schering Corp Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.
EP0567576B1 (en) 1991-01-16 1995-01-04 Schering Corporation Treatment of neoplastic disease with interleukin-10
US5624823A (en) 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994004180A2 (en) * 1992-08-20 1994-03-03 Schering Corporation Novel uses of il-4 and/or il-10, and antibodies against the same
EP0681589A1 (en) * 1993-02-01 1995-11-15 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5552303A (en) 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
WO1994022473A1 (en) 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5665345A (en) 1993-05-24 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting viral replication using IL-10
HUT73463A (en) 1993-07-26 1996-08-28 Schering Corp Agonists and antagonists of human interleukin-10
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
SK91696A3 (en) 1994-01-20 1997-04-09 Schering Plough Corp Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
US5696234A (en) 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5866134A (en) 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
US5770190A (en) 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US20050025742A1 (en) 1996-01-08 2005-02-03 Canji, Inc. Methods and compositions for interferon therapy
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6248514B1 (en) 1996-07-09 2001-06-19 Canji, Inc. Methods for measuring viral infectivity
US5759859A (en) 1996-07-15 1998-06-02 United States Of America As Represented By The Secretary Of The Army Sensor and method for detecting trace underground energetic materials
US5945097A (en) 1996-09-06 1999-08-31 Schering Corporation Method for lowering cholesterol levels with interleukin-10
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
US20030060434A1 (en) 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
NZ502375A (en) 1997-07-14 2001-11-30 Bolder Biotechnology Inc The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
CA2316834C (en) 1998-01-07 2006-01-03 Shearwater Polymers, Inc. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
US5994134A (en) 1998-05-04 1999-11-30 Canji, Inc. Viral production process
WO2000022124A2 (en) 1998-10-15 2000-04-20 Canji, Inc. Methods and compositions to induce antitumor response
ES2279636T3 (es) 1998-10-15 2007-08-16 Canji, Inc. Vectores viricos de replicacion selectiva.
US7001770B1 (en) 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
EP1131458A1 (en) 1998-11-18 2001-09-12 CANJI, Inc. Viral vectors with late transgene expression
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US6685931B1 (en) 1998-12-22 2004-02-03 Schering Corporation Treatment of hepatitis C virus infections with interleukin-10
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
WO2000071718A1 (en) 1999-05-25 2000-11-30 Canji, Inc. Gene therapy of pulmonary disease
WO2001005821A2 (en) 1999-07-16 2001-01-25 Maria Teresa Bejarano Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis
US6464976B1 (en) 1999-09-07 2002-10-15 Canji, Inc. Methods and compositions for reducing immune response
CA2386626A1 (en) 1999-10-15 2001-04-26 Richard Murphy Targeted vectors
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US20030186386A1 (en) 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
WO2001058950A1 (en) 2000-02-11 2001-08-16 Maxygen Aps Improved interleukin 10
AU8640501A (en) * 2000-07-31 2002-02-13 Univ Yale Innate immune system-directed vaccines
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
US20020081736A1 (en) 2000-11-03 2002-06-27 Conroy Susan E. Nucleic acid delivery
JP2002142770A (ja) 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
AU2002307497A1 (en) 2001-04-23 2002-11-05 The Regents Of The University Of California Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
EP1391513A1 (en) 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
CA2498319A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20040142893A1 (en) * 2002-10-21 2004-07-22 Uichi Ikeda Methods for treating and preventing vascular disease
WO2004044006A1 (en) 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
ATE404196T1 (de) 2002-11-29 2008-08-15 Maria Grazia Roncarolo Rapamycin und il-10 zur behandlung von autoimmunerkrankungen
AU2003303222A1 (en) 2002-12-19 2004-07-14 Universiteit Gent Mutant proteins showing increased secretion
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
TWI364295B (en) 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
SI2949658T1 (sl) 2003-03-03 2018-10-30 Dyax Corp. Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe
WO2004091517A2 (en) 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2005033307A1 (ja) 2003-09-30 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 新規のリフォールディング方法およびその方法によって得られたタンパク質
US8133700B2 (en) 2003-11-28 2012-03-13 The University Of Sydney Latent phase viral interleukin-10-(VII-10) and uses thereof
CA2551915C (en) 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
US20060078942A1 (en) 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
WO2005092928A1 (en) 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
EP2409713B1 (en) 2004-08-10 2015-07-22 Genzyme Corporation Oligonucleotides for use in modulating lipoprotein and cholesterol levels in humans
US20060046961A1 (en) 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN100334112C (zh) 2004-10-15 2007-08-29 上海海欣生物技术有限公司 人白细胞介素15与Fc融合蛋白
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
EP1831352B1 (en) 2004-12-13 2011-07-13 CANJI, Inc. Cell lines for production of replication-defective adenovirus
GB0500643D0 (en) 2005-01-13 2005-02-23 Renovo Ltd Medicaments
WO2006094530A1 (en) 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
KR101324451B1 (ko) * 2005-03-15 2013-10-31 가니얼 이뮤노테라퓨틱스 인코포레이티드 면역 조절제 활성을 갖는 화합물
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
WO2006119170A2 (en) 2005-05-02 2006-11-09 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
EP1891103B1 (en) * 2005-05-31 2009-12-23 The Regents of the University of Colorado Mutant il-10
US8945857B2 (en) 2005-07-01 2015-02-03 John Schrader Methods of isolating cells and generating monoclonal antibodies
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
PL1931704T3 (pl) 2005-10-04 2011-06-30 Zymogenetics L L C Wytwarzanie i oczyszczanie IL-29
WO2007061657A2 (en) 2005-11-14 2007-05-31 The Brigham & Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
JP5097714B2 (ja) 2005-12-12 2012-12-12 カンジ，インコーポレイテッド Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター
US7868139B2 (en) 2006-01-24 2011-01-11 Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
WO2007139178A1 (ja) * 2006-05-31 2007-12-06 Dnavec Corporation アルツハイマー病治療薬
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
JP2010504979A (ja) 2006-09-29 2010-02-18 カンジ，インコーポレイテッド 遺伝子治療のための方法および組成物
WO2008041953A2 (en) 2006-10-05 2008-04-10 Agency For Science, Technology And Research Dengue diagnosis and treatment
ES2409756T3 (es) 2006-12-04 2013-06-27 Promedior, Inc. Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos
JP2010516707A (ja) 2007-01-19 2010-05-20 カイ ファーマシューティカルズ インコーポレーティッド ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
DE08786222T1 (de) 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
WO2009036568A1 (en) 2007-09-19 2009-03-26 University Health Network Methods and compositions for treating tumors and viral infections
WO2009052454A2 (en) 2007-10-19 2009-04-23 University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
WO2009062151A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
HUE037936T2 (hu) 2008-12-17 2018-09-28 Merck Sharp & Dohme Mono- és di-pegil IL-10 elõállítása és alkalmazása
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
BR112012008665A2 (pt) 2009-10-12 2016-11-22 Pfizer tratamento de câncer
CN105567699A (zh) 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 白蛋白变体
CN102711829B (zh) 2009-11-30 2016-03-16 生物测试股份公司 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体
CA3083324A1 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
AU2011268310A1 (en) 2010-06-16 2013-01-10 Abbvie Inc. Comparison of protein samples
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
KR101884654B1 (ko) 2010-07-09 2018-08-02 애피바디 에이비 폴리펩타이드
US8759617B2 (en) 2010-09-21 2014-06-24 National Institute Of Agrobiological Sciences Method for extraction and purification of recombinant proteins from transgenic plants
ES2641869T3 (es) 2010-09-28 2017-11-14 Aegerion Pharmaceuticals, Inc. Polipéptidos de fusión de leptina-ABD con duración de acción aumentada
CN103370083B (zh) 2010-09-28 2016-11-16 艾米琳制药有限责任公司 具有增强的作用持续时间的工程化多肽
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
GB201018289D0 (en) * 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
BR112013024395B1 (pt) 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center Composições adotivas de imunoterapia celular e método para fabricação da dita composição
CN102145178B (zh) 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
WO2013012414A1 (en) 2011-07-18 2013-01-24 Medimmune, Llc Dosing regimens for treatment of cea-expressing cancers
US20140256626A1 (en) 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
US9714276B2 (en) 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
WO2013130913A1 (en) 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
WO2013169971A1 (en) 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
EP2947111B1 (en) 2013-01-17 2018-03-07 Xiamen Sinopeg Biotech Co., Ltd. Monofunctional branched polyethyleneglycol and bio-related substance modified by same
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
JP6660297B2 (ja) 2013-11-11 2020-03-11 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を処置するためのインターロイキン−１０の使用方法
WO2015108785A1 (en) 2014-01-15 2015-07-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
US20190290733A1 (en) 2015-03-11 2019-09-26 Nektar Therapeutics Conjugates of an il-7 moiety and a polymer
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer

Also Published As

Publication number Publication date
AU2014254019B2 (en) 2018-09-27
MX2015014438A (es) 2016-05-18
EP2986306A1 (en) 2016-02-24
US20160058838A1 (en) 2016-03-03
JP2019123719A (ja) 2019-07-25
EP2986306A4 (en) 2016-12-07
CN106913865A (zh) 2017-07-04
CN105209054A (zh) 2015-12-30
RU2679889C2 (ru) 2019-02-14
AU2014254019A1 (en) 2015-10-29
BR112015026122A2 (pt) 2017-07-25
WO2014172392A1 (en) 2014-10-23
US20180250364A1 (en) 2018-09-06
JP2016519108A (ja) 2016-06-30
RU2015149387A (ru) 2017-05-19
US20190314456A1 (en) 2019-10-17
US9943568B2 (en) 2018-04-17
CA2908198A1 (en) 2014-10-23
US10357545B2 (en) 2019-07-23
HK1215681A1 (zh) 2016-09-09

Similar Documents

Publication Publication Date Title
BR112015026122A8 (pt) agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit
EA201800199A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и снижения веса, композиции, лекарственное стедство
CY1123688T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20
BR112018074155A2 (pt) anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
UY35907A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmaceuticas que las contienen, así como su uso para la preparación de medicamentos
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
EA201991484A1 (ru) Лекарственные формы энзалутамида
MY188139A (en) Sodium channel modulators for the treatment of pain
BR112015006828A8 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112017005209A2 (pt) compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso
EP4252742A3 (en) Fluticasone furoate in the treatment of copd
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
BR112017005666A2 (pt) micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
NZ726132A (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2666 DE 08-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.